Kristina Chen1, Alan Krasner2,3, Nanxin Li4, Cheryl Q Xiang4, Todor Totev4, Jipan Xie5. 1. Outcomes Research and Epidemiology, Shire Human Genetic Therapies, Inc, a member of the Takeda group of companies , Cambridge , MA , USA. 2. Global Clinical Development, Crinetics Pharmaceuticals , San Diego , CA , USA. 3. Global Clinical Development, Shire Human Genetic Therapies, Inc, a member of the Takeda group of companies , Lexington , MA , USA. 4. Healthcare Practice, Analysis Group Inc , Boston , MA , USA. 5. Healthcare Practice, Analysis Group Inc , Los Angeles , CA , USA.
Abstract
Aims: To assess the real-world clinical burden and healthcare resource utilization (HRU) among patients with chronic hypoparathyroidism, overall and by adequately controlled (AC) vs not adequately controlled (NAC) disease, informed by guideline-recommended clinical management targets, including biochemistry and symptoms. Materials and methods: In this retrospective online chart review, endocrinologists in the US, Canada, the UK, France, Germany, Italy, and Spain were randomly selected to review the medical charts of adult patients with chronic hypoparathyroidism receiving calcium and activated vitamin D. Patients' demographics, disease characteristics, symptoms, comorbidities, and hypoparathyroidism-related HRU during the 1 year before the review date were assessed. Clinical burden and HRU were compared between patients with NAC and AC hypoparathyroidism. Results: Of 614 patients with hypoparathyroidism (AC, N = 442; NAC, N = 172), the mean age was 43.6 years, and the majority were female (61.6%), Caucasian (78.8%), and had post-surgical hypoparathyroidism (74.4%). Mean duration of hypoparathyroidism was 46.0 months. Hypoparathyroidism-related symptoms and comorbidities were reported in 59.4% and 46.7% of patients, respectively; 90.7% of patients had ≥1 hypoparathyroidism-related HRU event. More patients with NAC (57.6%) vs AC (42.5%) hypoparathyroidism experienced ≥1 comorbidity including calcium/phosphate imbalances, and brain, cardiovascular, metabolic, and renal disorders (all p < 0.01). More patients with NAC vs AC hypoparathyroidism incurred ≥1 hypoparathyroidism-related hospitalization (27.9% vs 16.3%) and emergency room visits (47.7% vs 38.5%), and patients with NAC vs AC hypoparathyroidism had a higher number of outpatient visits (3.6 vs 2.6; all p < 0.05), in the 1-year observation period. Limitations and conclusions: Limitations of this online chart review include possible under-estimation of disease burden, limited sample size, and the inability to rule out selection bias. Findings indicate that patients with chronic hypoparathyroidism experience substantial symptomatic and comorbid burdens resulting in frequent HRU, suggesting an unmet need, particularly in NAC disease.
Aims: To assess the real-world clinical burden and healthcare resource utilization (HRU) among patients with chronic hypoparathyroidism, overall and by adequately controlled (AC) vs not adequately controlled (NAC) disease, informed by guideline-recommended clinical management targets, including biochemistry and symptoms. Materials and methods: In this retrospective online chart review, endocrinologists in the US, Canada, the UK, France, Germany, Italy, and Spain were randomly selected to review the medical charts of adult patients with chronic hypoparathyroidism receiving calcium and activated vitamin D. Patients' demographics, disease characteristics, symptoms, comorbidities, and hypoparathyroidism-related HRU during the 1 year before the review date were assessed. Clinical burden and HRU were compared between patients with NAC and AChypoparathyroidism. Results: Of 614 patients with hypoparathyroidism (AC, N = 442; NAC, N = 172), the mean age was 43.6 years, and the majority were female (61.6%), Caucasian (78.8%), and had post-surgical hypoparathyroidism (74.4%). Mean duration of hypoparathyroidism was 46.0 months. Hypoparathyroidism-related symptoms and comorbidities were reported in 59.4% and 46.7% of patients, respectively; 90.7% of patients had ≥1 hypoparathyroidism-related HRU event. More patients with NAC (57.6%) vs AC (42.5%) hypoparathyroidism experienced ≥1 comorbidity including calcium/phosphate imbalances, and brain, cardiovascular, metabolic, and renal disorders (all p < 0.01). More patients with NAC vs AChypoparathyroidism incurred ≥1 hypoparathyroidism-related hospitalization (27.9% vs 16.3%) and emergency room visits (47.7% vs 38.5%), and patients with NAC vs AChypoparathyroidism had a higher number of outpatient visits (3.6 vs 2.6; all p < 0.05), in the 1-year observation period. Limitations and conclusions: Limitations of this online chart review include possible under-estimation of disease burden, limited sample size, and the inability to rule out selection bias. Findings indicate that patients with chronic hypoparathyroidism experience substantial symptomatic and comorbid burdens resulting in frequent HRU, suggesting an unmet need, particularly in NAC disease.
Authors: Juan J Díez; Emma Anda; Julia Sastre; Begoña Pérez Corral; Cristina Álvarez-Escolá; Laura Manjón; Miguel Paja; Marcel Sambo; Piedad Santiago Fernández; Concepción Blanco Carrera; Juan C Galofré; Elena Navarro; Carles Zafón; Eva Sanz; Amelia Oleaga; Orosia Bandrés; Sergio Donnay; Ana Megía; María Picallo; Cecilia Sánchez Ragnarsson; Gloria Baena-Nieto; José Carlos Fernández-García; Beatriz Lecumberri; Manel Sahún de la Vega; Ana R Romero-Lluch; Pedro Iglesias Journal: Gland Surg Date: 2020-10
Authors: Neil Gittoes; Lars Rejnmark; Steven W Ing; Maria Luisa Brandi; Sigridur Björnsdottir; Stefanie Hahner; Lorenz C Hofbauer; Pascal Houillier; Aliya A Khan; Michael A Levine; Michael Mannstadt; Dolores M Shoback; Tamara J Vokes; Pinggao Zhang; Claudio Marelli; John Germak; Bart L Clarke Journal: BMC Endocr Disord Date: 2021-11-20 Impact factor: 2.763